Why Ausnet, Charter Hall, Codan, and Imugene shares are storming higher

These ASX shares are starting the week strongly…

| More on:
stock market gaining

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing, the benchmark index is up 0.8% to 7,382.5 points.

Four ASX shares that are climbing more than most today are listed below. Here's why they are storming higher:

Ausnet Services Ltd (ASX: AST)

The Ausnet share price is up almost 4% to $2.57. The catalyst for this was news that the electricity distribution networks company has accepted a takeover offer from Brookfield Asset Management. According to the release, Brookfield has tabled a binding proposal of $2.65 per share, which is up from its original offer of $2.50 per share. As part of the terms of the agreement, Ausnet has terminated its due diligence process with APA Group (ASX: APA).

Charter Hall Group (ASX: CHC)

The Charter Hall share price is up over 4% to $18.07. Investors have been buying this property company's shares after it upgraded its post-tax operating earnings per security (OEPS) guidance. Charter Hall now expects OEPS of no less than 83 cents per share in FY 2022, which represents a minimum 36% year on year growth rate.

Codan Limited (ASX: CDA)

The Codan share price is up 4.5% to $10.51. This gain appears to have been driven by bargain hunters swooping in after the metal detector company's shares were sold off last week. The Codan share price sank 23% last week following the release of its annual general meeting update.

Imugene Limited (ASX: IMU)

The Imugene share price has jumped 7% to 53 cents. This morning Imugene announced a strategic collaboration with Eureka Therapeutics. The collaboration will evaluate Eureka's anti-CD19 Artemis T-cell therapy in combination with Imugene's CD19-expressing oncolytic virus onCARlytics in solid tumours. Eureka Therapeutics is a US based clinical-stage biotechnology company focused on developing novel cancer T-cell therapies to treat cancers.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »